Cargando…
Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
BACKGROUND: JX594 is an oncolytic poxvirus derived from Wyeth strain vaccinia virus. We reported the presentation of cutaneous and mucosal pustules containing laboratory-confirmed JX594 in a patient following injection of JX594. CASE PRESENTATION: A 36-year-old man was diagnosed hepatitis B virus-as...
Autores principales: | Kung, Che-Hsuan, Kuo, Shu-Chen, Chen, Te-Li, Weng, Wen-Sung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608268/ https://www.ncbi.nlm.nih.gov/pubmed/26471278 http://dx.doi.org/10.1186/s12885-015-1753-4 |
Ejemplares similares
-
Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma
por: Lun, XueQing, et al.
Publicado: (2010) -
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015) -
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
por: Parato, Kelley A, et al.
Publicado: (2012) -
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022) -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)